BIOMAY LAUNCHES FDA-GRADE CRISPR/CAS9 NUCLEASE FOR OFF-THE-SHELF PURCHASE

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Biomay AG

Logo

Tags

Medical profession

Research

More Like This

News Aktuell associated0

BIOMAY OBTAINS FDA APPROVAL FOR MANUFACTURING OF CAS9 NUCLEASE AT HEADQUARTERS SITE

PR Newswire associated0

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication

PR Newswire associated0

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

NAYO to Announce the Launch of Fully Automated Biobanking Solutions in Europe at Medica 2024